Published in Nicotine Tob Res on November 22, 2010
Nicotine-induced upregulation of native neuronal nicotinic receptors is caused by multiple mechanisms. J Neurosci (2012) 1.12
Developmental effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Neurobiol Learn Mem (2012) 1.01
Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. J Pharmacol Exp Ther (2012) 0.99
Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment. Neuropharmacology (2013) 0.98
Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers. J Psychopharmacol (2012) 0.97
Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements. Alcohol Clin Exp Res (2012) 0.93
Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology (2012) 0.92
Genetic background influences the effects of withdrawal from chronic nicotine on learning and high-affinity nicotinic acetylcholine receptor binding in the dorsal and ventral hippocampus. Psychopharmacology (Berl) (2012) 0.90
Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice. PLoS One (2015) 0.88
Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence. Mol Psychiatry (2013) 0.87
Effects of chronic low- and high-dose nicotine on cognitive flexibility in C57BL/6J mice. Behav Brain Res (2012) 0.86
A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain. Neuropsychopharmacology (2012) 0.85
Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal. Neuropsychopharmacology (2013) 0.84
Morphine dependence and withdrawal induced changes in cholinergic signaling. Pharmacol Biochem Behav (2013) 0.84
Effects of sazetidine-A, a selective α4β2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats. Eur J Pharmacol (2012) 0.83
Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors. J Pharmacol Exp Ther (2014) 0.82
Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain. J Neurochem (2014) 0.80
The Nicotine Metabolite, Cotinine, Alters the Assembly and Trafficking of a Subset of Nicotinic Acetylcholine Receptors. J Biol Chem (2015) 0.79
Dissociation of tolerance and nicotine withdrawal-associated deficits in contextual fear. Brain Res (2014) 0.79
Predicted Impact of Nicotine Reduction on Smokers with Affective Disorders. Tob Regul Sci (2015) 0.79
Nicotine withdrawal. Curr Top Behav Neurosci (2015) 0.78
Chronic treatment with varenicline changes expression of four nAChR binding sites in mice. Neuropharmacology (2015) 0.78
Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats. Behav Brain Res (2014) 0.78
Varenicline and nicotine enhance GABAergic synaptic transmission in rat CA1 hippocampal and medial septum/diagonal band neurons. Life Sci (2013) 0.77
Varenicline and cytisine: two nicotinic acetylcholine receptor ligands reduce ethanol intake in University of Chile bibulous rats. Psychopharmacology (Berl) (2013) 0.77
Anxiolytic- and antidepressant-like effects of the methadone metabolite 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP). Neuropharmacology (2015) 0.77
Endogenously expressed muscarinic receptors in HEK293 cells augment up-regulation of stably expressed α4β2 nicotinic receptors. J Biol Chem (2011) 0.77
Long-lasting effects of adolescent oxycodone exposure on reward-related behavior and gene expression in mice. Psychopharmacology (Berl) (2016) 0.76
Effects of the BDNF Val66Met Polymorphism on Anxiety-Like Behavior Following Nicotine Withdrawal in Mice. Nicotine Tob Res (2015) 0.76
Distinct Roles of CREB within the Ventral and Dorsal Hippocampus in Mediating Nicotine Withdrawal Phenotypes. Neuropsychopharmacology (2016) 0.75
Nicotinic Acetylcholine Receptors as Targets for Tobacco Cessation Therapeutics: Cutting-Edge Methodologies to Understand Receptor Assembly and Trafficking. Neuromethods (2016) 0.75
Thyroid hormone signaling: Contribution to neural function, cognition, and relationship to nicotine. Neurosci Biobehav Rev (2015) 0.75
Withdrawal From Chronic Nicotine Reduces Thyroid Hormone Levels and Levothyroxine Treatment Ameliorates Nicotine Withdrawal-Induced Deficits in Hippocampus-Dependent Learning in C57BL/6J Mice. Nicotine Tob Res (2014) 0.75
Putative Epigenetic Involvement of the Endocannabinoid System in Anxiety- and Depression-Related Behaviors Caused by Nicotine as a Stressor. PLoS One (2016) 0.75
Selective and regulated trapping of nicotinic receptor weak base ligands and relevance to smoking cessation. Elife (2017) 0.75
Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med (2000) 12.83
Cigarette smoking among adults--United States, 2006. MMWR Morb Mortal Wkly Rep (2007) 8.14
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol (1992) 3.20
Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) (2009) 2.76
Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci (2005) 2.59
Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry (2008) 2.29
Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport (2002) 2.28
Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav (1991) 2.04
Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther (1983) 2.03
Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci (2007) 1.88
Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos (2005) 1.82
Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science (1983) 1.78
Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther (1999) 1.73
Nicotine dependence, depression, and gender: characterizing phenotypes based on withdrawal discomfort, response to smoking, and ability to abstain. Nicotine Tob Res (2005) 1.70
Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol Pharmacol (2006) 1.62
beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry (2009) 1.53
Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav (2008) 1.52
Hedonic capacity, cigarette craving, and diminished positive mood. Nicotine Tob Res (2004) 1.51
A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf (2009) 1.50
The role of alpha6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. J Pharmacol Exp Ther (2009) 1.45
Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol (1986) 1.38
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol (2009) 1.37
A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur J Pharmacol (2006) 1.29
Increases in hyperactive-impulsive symptoms predict relapse among smokers in nicotine replacement therapy. J Subst Abuse Treat (2005) 1.28
Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior. J Pharmacol Exp Ther (2010) 1.24
Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. Behav Pharmacol (2008) 1.23
Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology (2008) 1.20
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol (2009) 1.19
5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice. Jpn J Pharmacol (1995) 1.15
Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res (2010) 1.11
Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry (2009) 1.09
Regulation of neuronal nicotinic receptor traffic and expression. Brain Res Rev (2007) 1.08
Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. Naunyn Schmiedebergs Arch Pharmacol (1998) 0.94
Sensitivity to nicotine and brain nicotinic receptors are altered by chronic nicotine and mecamylamine infusion. J Pharmacol Exp Ther (1994) 0.93
Effects of chronic administration of nicotine on prolactin release in the rat: inactivation of prolactin response by repeated injections of nicotine. J Pharmacol Exp Ther (1990) 0.87
In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. Nucl Med Biol (2001) 0.84
Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A (2009) 1.76
cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci (2002) 1.71
cAMP response element-binding protein is required for stress but not cocaine-induced reinstatement. J Neurosci (2004) 1.59
OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend (2010) 1.55
Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat Neurosci (2011) 1.53
Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron (2005) 1.45
Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci (2008) 1.41
Genetic evidence for a role of CREB in sustained cortical arousal. J Neurophysiol (2003) 1.37
Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology (Berl) (2005) 1.37
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29
Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci (2005) 1.24
Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior. J Pharmacol Exp Ther (2010) 1.24
cAMP response element-binding protein deficiency allows for increased neurogenesis and a rapid onset of antidepressant response. J Neurosci (2007) 1.23
The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res (2011) 1.18
Endocrine and gene expression changes following forced swim stress exposure during cocaine abstinence in mice. Psychopharmacology (Berl) (2008) 1.14
Making a bad thing worse: adverse effects of stress on drug addiction. J Clin Invest (2008) 1.13
Activating transcription factor 1 and CREB are important for cell survival during early mouse development. Mol Cell Biol (2002) 1.11
Molecular and genetic substrates linking stress and addiction. Brain Res (2009) 1.11
NAC1 regulates the recruitment of the proteasome complex into dendritic spines. J Neurosci (2007) 1.08
A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. Biochem J (2012) 1.06
Ventral tegmental afferents in stress-induced reinstatement: the role of cAMP response element-binding protein. J Neurosci (2010) 1.06
Effects of the histone deacetylase inhibitor sodium butyrate in models of depression and anxiety. Neuropharmacology (2009) 1.06
Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc Natl Acad Sci U S A (2012) 1.02
Developmental effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Neurobiol Learn Mem (2012) 1.01
Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. J Pharmacol Exp Ther (2012) 0.99
Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology (2006) 0.99
Stress-induced potentiation of cocaine reward: a role for CRF R1 and CREB. Neuropsychopharmacology (2009) 0.99
Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors. Neuropharmacology (2010) 0.99
CREB gene transcription factors: role in molecular mechanisms of alcohol and drug addiction. Alcohol Clin Exp Res (2005) 0.98
Differential distribution of CREB in the mesolimbic dopamine reward pathway. J Neurochem (2003) 0.96
Behavioral and activity assessment of laboratory mice (Mus musculus) after tail biopsy under isoflurane anesthesia. J Am Assoc Lab Anim Sci (2011) 0.96
Inducible cAMP early repressor regulates corticosterone suppression after tricyclic antidepressant treatment. J Neurosci (2004) 0.93
Augmented responses to morphine and cocaine in mice with a 12-lipoxygenase gene disruption. Psychopharmacology (Berl) (2003) 0.93
Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology (2012) 0.92
Genetic background influences the effects of withdrawal from chronic nicotine on learning and high-affinity nicotinic acetylcholine receptor binding in the dorsal and ventral hippocampus. Psychopharmacology (Berl) (2012) 0.90
Selective deletion of a cell cycle checkpoint kinase (ATR) reduces neurogenesis and alters responses in rodent models of behavioral affect. Neuropsychopharmacology (2011) 0.89
Differential effects of acute and repeated citalopram in mouse models of anxiety and depression. Int J Neuropsychopharmacol (2009) 0.89
Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology (2012) 0.88
Cocaine-related behaviors in mice with deficient gliotransmission. Psychopharmacology (Berl) (2012) 0.88
Alterations in morphine-induced reward, locomotor activity, and thermoregulation in CREB-deficient mice. Brain Res (2005) 0.87
Regulation of antidepressant activity by cAMP response element binding proteins. Mol Neurobiol (2004) 0.87
Decreased CREB levels suppress epilepsy. Neurobiol Dis (2011) 0.86
Sex differences in response to nicotine in C57Bl/6:129SvEv mice. Nicotine Tob Res (2009) 0.86
Parkinson's disease-like neuromuscular defects occur in prenyl diphosphate synthase subunit 2 (Pdss2) mutant mice. Mitochondrion (2011) 0.85
Increased hippocampal neurogenesis and accelerated response to antidepressants in mice with specific deletion of CREB in the hippocampus: role of cAMP response-element modulator τ. J Neurosci (2013) 0.85
Depressive phenotypes evoked by experimental diabetes are reversed by insulin. Physiol Behav (2011) 0.84
Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal. Neuropsychopharmacology (2013) 0.84
Requirement for the POZ/BTB protein NAC1 in acute but not chronic psychomotor stimulant response. Behav Brain Res (2007) 0.83
μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. Psychopharmacology (Berl) (2012) 0.82
Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors. J Pharmacol Exp Ther (2014) 0.82
Brain region- and sex-specific alterations in DAMGO-stimulated [(35) S]GTPγS binding in mice with Oprm1 A112G. Addict Biol (2012) 0.82
Enhanced extinction of cocaine seeking in brain-derived neurotrophic factor Val66Met knock-in mice. Eur J Neurosci (2012) 0.80
Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain. J Neurochem (2014) 0.80
Brain monoamines and antidepressant-like responses in MRL/MpJ versus C57BL/6J mice. Neuropharmacology (2012) 0.79
CREB-mediated alterations in the amygdala transcriptome: coordinated regulation of immune response genes following cocaine. Int J Neuropsychopharmacol (2010) 0.77
Translational research in nicotine dependence. Cold Spring Harb Perspect Med (2013) 0.77
Targeted gene mutation of E2F1 evokes age-dependent synaptic disruption and behavioral deficits. J Neurochem (2014) 0.77
Translating basic science to improve pharmacotherapy for nicotine dependence. Nicotine Tob Res (2007) 0.76
Not all stress is equal: CREB is not necessary for restraint stress reinstatement of cocaine-conditioned reward. Behav Brain Res (2013) 0.76
The role of cAMP response element-binding proteins in mediating stress-induced vulnerability to drug abuse. Int Rev Neurobiol (2005) 0.76